-+ 0.00%
-+ 0.00%
-+ 0.00%

Theriva Biologics To Present VCN-12 And VCN-01 Preclinical Data At ESGCT, Highlighting Novel Antitumor Mechanism And Intracranial Feasibility For Brain Tumors

Benzinga·10/06/2025 12:03:45
Listen to the news

- Preclinical data for VCN-12, the next candidate from Theriva's VCN-X discovery program, highlight a novel mechanism of action with the potential to significantly improve antitumor effects -

- Pre-ESGCT meeting monograph includes preclinical data demonstrating the feasibility of VCN-01 intracranial administration for the potential treatment of brain tumors -

ROCKVILLE, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE:TOVX), ("Theriva" or the "Company"), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced an upcoming presentation at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), to be held in Seville, Spain from 7-10 October 2025.

Co-founder of VCN Biosciences S.L. (now Theriva Biologics S.L.) Dr. Ramón Alemany - Head of the Immunotherapy and Virotherapy Group at the ProCURE Program of the Catalan Institute of Oncology (ICO) and the Oncobell Program of the Biomedical Research Institute of Bellvitge (IDIBELL) in Barcelona - will present new mechanistic and preclinical data for VCN-12, a next generation oncolytic adenovirus selected from Theriva's VCN-X discovery program. VCN-12 is derived from lead clinical product VCN-01 (zabilugene almadenorepvec) and is armed with additional transgenes designed to improve tumor cell lysis, enhance stroma degradation, and augment the antitumor immune response.